drugset

drugset / Trial / NCT01349036

A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma

NCT01349036 ↗

Phase 2 Terminated 38 enrolled Daiichi Sankyo Plexxikon · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the response of subjects with recurrent glioblastoma to continuous therapy of PLX3397.

Timeline

Start: 2011-12-03
Primary completion: 2013-11-05
Completion: 2013-11-05

Publications

Background Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD; North American Brain Tumor Consortium. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008 Apr;10(2):162-70. doi: 10.1215/15228517-2007-062. Epub 2008 Mar 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pexidartinib	Small molecule	—	Oral

Indications